Apellis Pharmaceuticals, Inc.
APLS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.23 | -0.05 | 0.74 |
| FCF Yield | 3.80% | 0.20% | -1.95% | 0.49% |
| EV / EBITDA | 10.91 | -75.77 | -35.51 | -166.58 |
| Quality | ||||
| ROIC | 25.30% | -5.36% | -13.15% | -3.70% |
| Gross Margin | 94.58% | 92.12% | 79.40% | 80.78% |
| Cash Conversion Ratio | 0.50 | -0.11 | 0.58 | -0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | 55.01% | 59.92% | 94.23% | 118.00% |
| Free Cash Flow Growth | 2,364.06% | 108.23% | -376.20% | -43.28% |
| Safety | ||||
| Net Debt / EBITDA | -1.60 | -3.27 | -1.38 | -2.43 |
| Interest Coverage | 19.79 | -2.98 | -7.54 | -2.27 |
| Efficiency | ||||
| Inventory Turnover | 0.20 | 0.12 | 0.42 | 0.50 |
| Cash Conversion Cycle | 376.79 | 542.55 | 203.06 | 209.42 |